Document is current
Any future updates will be listed below
-
Authors
Naganawa, Mika https://orcid.org/0000-0002-4408-2621
Gallezot, Jean-Dominique
Li, Songye
Nabulsi, Nabeel B.
Henry, Shannan
Cai, Zhengxin
Matuskey, David
Huang, Yiyun
Carson, Richard E.
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG052560, R01AG065474)
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 12 August 2024
First Online: 19 August 2024
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Yale University Human Investigation Committee and the Yale‑New Haven Hospital Radiation Safety Committee.
: Written informed consent was obtained from all subjects.
: The radioligand [<sup>18</sup>F]SynVesT-1 (formerly referred to as [<sup>18</sup>F]SDM-8) is contained in the international patent application PCT/US2018/018388, “Radiolabeled Pharmaceuticals and Methods of Making and Using Same,” filed on February 15, 2018 (inventors: Yiyun Huang, Zhengxin Cai, Songye Li, Nabeel Nabulsi, and Richard E. Carson). No other potential conflict of interest relevant to this article was reported.
